Healthcare M&A has been on a tear in 2014. Not to be left out, Abbott Labs' (NYSE: ABT) recently announced a $2.9 billion acquisition of the Chilean generic drug maker CFR Pharmaceuticals.
This deal is a solid win for Abbott. It gains increased access to the fast growing Latin American market, adds scale to its generic drug business, and will be accretive to next year's earnings.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss the deal details along with why it makes one of the most attractive things about Abbott Labs even better.
David Williamson owns shares of Abbott Laboratories and AbbVie.. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.